

Systemic Inflammation in Pregnant Women with and without Latent Tuberculosis Infection

Shilpa Naik^{1,2}, Mallika Alexander¹, Pavan Kumar³, Vandana Kulkarni¹, Su Yadana⁴, Ramesh Bhosale^{1,2}, Subash Babu³, Amita Gupta^{1,5}, Jyoti Mathad⁶ and Rupak Shivakoti⁴
 Institutions: ¹Byramjee-Jeejeebhoy Government Medical college-Johns Hopkins University Clinical Research Site, Pune, India, ²Byramjee Jeejeebhoy Government Medical College, Pune, India, ³National Institutes of Health, National Institute for Research in Tuberculosis, International Center for Excellence in Research, Chennai, India, ⁴Columbia University Mailman School of Public Health, New York, USA, ⁵Johns Hopkins University School of Medicine, Baltimore, USA, ⁶Weill Cornell Medical College, New York, USA. E-mail: rs3895@cumc.columbia.edu

E-Poster No. EP27-357-23

THE 51ST UNION
 WORLD CONFERENCE
 ON LUNG HEALTH

Intro

Recent studies show increased systemic inflammation in adults with latent tuberculosis infection (LTBI+) compared to those without (LTBI-)

Potential differences in systemic inflammation by LTBI status has not been assessed in pregnant women

It is also not known whether potential differences in systemic inflammation during pregnancy is linked to the increased progression of TB observed in pregnant and postpartum women

The objective of this study was to address this research gap and determine potential differences in systemic inflammation by LTBI status

An secondary objective was to explore the association of systemic inflammation with TB progression

Methods

We conducted a cohort study of 155 LTBI+ and 65 LTBI- pregnant women, stratified by HIV status attending an antenatal clinic at BJ Medical College in Pune, India

Women were enrolled in second or third trimester, and had their LTBI status assessed by IRGA test

Plasma samples were used to measure markers of systemic inflammation through immunoassays: IFN β , CRP, AGP, I-FABP, IFN γ , IL-1 β , sCD14, sCD163, TNF α , IL-6, IL17a and IL-13

Univariable and Multivariable linear regression models were fit to test the association of LTBI status with each inflammation marker

Results




Figure 1: Levels of third trimester inflammation by LTBI status (N=220)

Legend: A) Median and interquartile range (IQR) Log₂ levels of markers, measured in the 3rd trimester is shown for LTBI+ (n=155) and LTBI- (n=65) pregnant women. Wilcoxon rank-sum test was used to calculate p-values. *p < 0.05, **p < 0.01 and ***p < 0.001. B) Relative fold-change is shown for each marker by LTBI status. Red bars indicate p-value < 0.05.

biomarker	model	Mean change (95% CI)	p-value
AGP	univariate	-0.20 (-0.42 to 0.02)	0.08
	multivariate	-0.29 (-0.54 to -0.04)	0.02
I-FABP	univariate	-0.41 (-0.78 to -0.04)	0.03
	multivariate	-0.25 (-0.67 to 0.15)	0.22
IL-1 β	univariate	-1.03 (-1.53 to -0.54)	<0.001
	multivariate	-1.15 (-1.70 to -0.60)	<0.001
sCD163	univariate	-0.18 (-0.39 to 0.03)	0.10
	multivariate	-0.28 (-0.51 to -0.05)	0.02
TNF α	univariate	-0.19 (-0.49 to 0.10)	0.20
	multivariate	-0.24 (-0.57 to 0.10)	0.17
IL-6	univariate	-1.36 (-1.93 to -0.80)	<0.001
	multivariate	-1.22 (-1.87 to -0.58)	<0.001
IL-17a	univariate	-0.34 (-0.50 to -0.17)	<0.001
	multivariate	-0.39 (-0.57 to -0.21)	<0.001

Figure 2: Association of LTBI status with third trimester inflammation (N=220)

Legend: Using linear regression, the mean change in Log₂ concentrations of each inflammation marker and 95% confidence intervals (95% CI) among LTBI+ individuals compared to LTBI- individuals is shown in the forest plot. Inflammation markers were measured in samples collected at the third trimester of pregnancy. Multivariate models adjusted for age, MUAC, HIV status, diet and gestational diabetes status. Only immune markers with a p-value < 0.2 in the univariate model are shown.

biomarker	model	Odds ratio (95% CI)	value
I-FABP	univariate	1.63 (1.01 to 2.61)	0.04
	multivariate	1.50 (0.88 to 2.54)	0.13
IL-1 β	univariate	1.52 (0.99 to 2.30)	0.05
	multivariate	1.64 (1.05 to 2.57)	0.03
sCD163	univariate	2.02 (0.78 to 5.23)	0.15
	multivariate	2.10 (0.47 to 9.37)	0.33
IL-6	univariate	1.66 (1.15 to 2.40)	0.007
	multivariate	1.58 (1.05 to 2.39)	0.03
IL-17a	univariate	4.72 (1.06 to 21.06)	0.04
	multivariate	5.49 (0.84 to 35.97)	0.08
IL-13	univariate	1.96 (0.99 to 3.84)	0.05
	multivariate	2.43 (1.12 to 5.27)	0.02

Figure 3: Association of third trimester inflammation markers with TB progression (N=155; 9 progressors)

Legend: Using logistic regression, the odds ratio and 95% CI of TB progression per log₂ increase in each inflammation marker among LTBI+ pregnant women is shown in the forest plot. Progressors were defined as those who developed TB either during pregnancy (n=1) or post-partum (n=8). Inflammation markers were measured at the third trimester. Multivariable models adjusted for age, MUAC and HIV status.

Results and Discussion

Results:

- Study population characteristics were a median age of 23, 28% undernourished, 25% with less than secondary education, 7% with gestational diabetes and 32% with HIV (by design)
- In multivariable models, LTBI+ women had significantly lower levels of **second** trimester AGP, I-FABP, IL1 β , IL-6 and IL17a, and higher levels of IFN γ compared to LTBI- women
 - AGP, IL1 β , IL-6 and IL17a results were robust to Bonferroni corrections
- LTBI+ also had significantly lower levels of **third** trimester AGP, IL1 β , sCD163, IL-6 and IL-17a
 - IL1 β , IL-6 and IL-17a results were robust to Bonferroni corrections
- In exploratory analysis, there was a significantly increased odds of progression among LTBI+ pregnant women per log₂ increase in third trimester plasma levels of IL-1 β , IL-6 and IL-13 in multivariable models

Discussion:

- Interestingly, LTBI+ pregnant women had lower levels of various inflammatory cytokines in both the second and third trimester of pregnancy compared to LTBI- women
- Future studies in diverse settings should confirm these findings and also assess potential mechanisms
- Impact of these findings are not clear but our exploratory data analysis suggests that the systemic immune profile might be linked to progression of TB in pregnancy and postpartum
 - Future larger studies will need to confirm this
 - If confirmed, this profile could identify subsets of LTBI+ women at higher risk of TB progression
- In summary, we identify a unique systemic immune profile in LTBI+ pregnant women